Chan's reasoning: swine flu virus isn't growing very fast in laboratories, making it hard for scientists to get the key ingredient they need for a vaccine -- the "seed stock" from the virus. And she said it would then take months before a vaccine would be available, the Associated Press reported.
However, Jernigan said that in the United States, the steps needed to produce a swine flu vaccine are moving ahead on schedule, and a vaccine should be ready by the fall. "We are moving along and have not had significant delays here in the U.S. with the development of the vaccine candidates," he said.
Jernigan noted that creating a vaccine for the new H1N1 flu is a complicated process. He also suggested making the regular, seasonal flu vaccine available earlier to Americans than its usual late September or early October introduction.
"At this point when to vaccinate [with the new H1N1 vaccine] is going to be driven largely by when it's available," Jernigan said. "If possible we want to have an earlier roll-out of the seasonal influenza vaccine, to make it easier for an additional vaccine if that's the ultimate policy," he said.
"For that reason we will be working closely with manufacturers and with multiple advisory committees through the federal government and with other partners to make sure that what is recommended in terms of timing is feasible and can be initiated, to offer the most protection to the most folks," Jernigan said.
In the United States, most cases of swine flu continue to be no worse than seasonal flu, health officials said. Testing has also found that the swine flu virus remains susceptible to two common antiviral drugs, Tamiflu and Relenza, according to the CDC.
All rights reserved